Drug Profile
Research programme: RNAi Therapeutics - Halo-Bio
Latest Information Update: 30 Dec 2022
Price :
$50
*
At a glance
- Originator Halo-Bio RNAi Therapeutics; Tekmira Pharmaceuticals Corporation
- Developer Halo-Bio RNAi Therapeutics
- Class Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 30 Dec 2022 Early research in Cancer in Canada (Parenteral)
- 28 Aug 2020 No recent reports of development identified for research development in Unspecified in Canada (Parenteral)
- 12 Apr 2017 Halo-Bio's RNAi therapeutics are still in Research stage